RaNA Therapeutics

RaNA Therapeutics is pioneering the discovery of a new class of medicines that target RNA to selectively activate protein expression, thereby enabling the body to produce desirable proteins to treat or prevent disease. RaNA’s novel therapeutics work by precisely activating the expression of select genes within the patient’s own cells, increasing the synthesis of therapeutic proteins. The company’s proprietary RNA targeting technology works epigenetically to make it possible, for the first time, to increase the expression of therapeutic proteins with exquisite selectivity. RaNA is based in Cambridge, MA.


Team Member
more about
Jasper Bos
Latest News Entry
RaNA Therapeutics Secures $55 Million in Oversubscribed Series B Financing

Proceeds will Further Strengthen RaNA’s Proprietary Platform s and Advance Lead Optimization and IND - Enabling Studies for Priority Programs

all portfolio news